Oragenics Announces New Strategic Partnership with Central Business USA for South America

Oragenics Announces New Strategic Partnership with Central Business USA for South America

Oragenics, Inc.Michael Sullivan, 813-286-7900 x246Direct: 813-786-6431Chief Financial OfficerorLaunchPad IRRobert Giordano, 1-800-625-2236 x7770Direct: 917-327-3938President

. (OTCBB: ORNI) (the “Company”) a world leader in oral health probiotics for humans and companion pets, announced that it has entered into a new three year contract with Central Business USA. Under the terms of the agreement, Central Business USA will be the exclusive distributor of Oragenics’ Oral Care Probiotics for , and in Brazil, Argentina, Paraguay and Uruguay. All products will contain ®; the Company’s patented proprietary blend of three probiotics specifically designed for oral health.

Central Business USA is a US based pharmaceutical wholesaler located in Orlando, Florida that provides prescription medication, medical products, vitamins and supplements to the US and South American market. They specialize in "new medications” that are not yet available to hospitals, clinics and doctors.

"This latest agreement reinforces Oragenics’ strategy to continue to expand the oral probiotic product line in the international market. We are confident that in concert with Central Business USA, we can develop a substantial market in these four countries. This partnership positions the Company for further success," stated John N. Bonfiglio PhD, President and CEO of Oragenics.

Oragenics, Inc. is focused on becoming the world leader in probiotics for oral health for humans and pets and in novel antibiotics against infectious disease. Oragenics, Inc. develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names ® and ® in over 13 countries worldwide. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation, a synthetic biology company.

For more information, visit .

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.